Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 3/20 | 0.57 |
| ▸ | HTR6 | P50406 | 2/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.51 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.49 |
| ▸ | UQCRB | P14927 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | BRD1 | O95696 | 1/20 | 0.47 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.47 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.47 |
| ▸ | BRPF3 | Q9ULD4 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | FABP1 | P07148 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3194968 | 0.84 | NTSR1 (0.60) | SERPINE1NR1I2NTSR1 | |
| SCHEMBL3201141 | 0.83 | NTSR1 (0.75) | NTSR1 | |
| SCHEMBL3193216 | 0.83 | SERPINE1 (0.47) | SERPINE1HTR6NR1I2NTSR1PTGDR2 | |
| SCHEMBL3193674 | 0.81 | SERPINE1 (0.55) | SERPINE1HTR6NR1I2PLAUPOLB | |
| SCHEMBL14947702 | 0.80 | KMT2A (0.66) | HTR6NTSR1KMT2A | |
| SCHEMBL3152737 | 0.80 | HTR6 (0.80) | SERPINE1HTR6NR1I2PLAUBRD4 | |
| SCHEMBL3198713 | 0.79 | SERPINE1 (0.52) | SERPINE1HTR6NR1I2PTGDR2KMT2A | |
| SCHEMBL5418798 | 0.79 | SERPINE1 (0.56) | SERPINE1NR1I2UQCRBKMT2APOLB | |
| SCHEMBL3144022 | 0.78 | HTR6 (0.61) | SERPINE1HTR6NR1I2PTGDR2POLB | |
| SCHEMBL3195376 | 0.77 | SERPINE1 (0.52) | SERPINE1HTR6NR1I2PLAUPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137363-A1 | Substituted Indoles And Methods Of Their Use | WYETH LLC (US) | 2010-06-03 | — | — | US | claimed |
| EP-1919866-A2 | SUBSTITUTED INDOLES AND USE THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-05-14 | — | — | EP | claimed |
| US-20070043101-A1 | Substituted indoles and methods of their use | WYETH (US) | 2007-02-22 | — | — | US | claimed |
| WO-2007022321-A2 | SUBSTITUTED INDOLES AND USE THEREOF | WYETH (US) | 2007-02-22 | — | — | WO | claimed |
| US-20100137363-A1 | Substituted Indoles And Methods Of Their Use | WYETH LLC (US) | 2010-06-03 | — | — | US | disclosed |
| US-7683091-B2 | Substituted indoles and methods of their use | WYETH (US) | 2010-03-23 | — | — | US | disclosed |
| EP-1919866-A2 | SUBSTITUTED INDOLES AND USE THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-05-14 | — | — | EP | disclosed |
| US-20070043101-A1 | Substituted indoles and methods of their use | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007022321-A2 | SUBSTITUTED INDOLES AND USE THEREOF | WYETH (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043101-A1 | Substituted indoles and methods of their use | INMT, AANAT, IDO2 | SERPINE1 4756/4885HTR6 20/4885NR1I2 2818/4885 |
| US-20100137363-A1 | Substituted Indoles And Methods Of Their Use | INMT, AANAT, IDO2 | SERPINE1 4756/4885HTR6 20/4885NR1I2 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.